PF 06482077Alternative Names: PF-06482077
Latest Information Update: 15 Feb 2017
At a glance
- Originator Pfizer
- Class Antibacterials
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bacterial infections
Most Recent Events
- 31 Jan 2017 Phase-I clinical trials in Bacterial infections in USA before January 2017 (Pfizer pipeline, February 2017)